411
Views
109
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES Clinical Translational Therapeutics

Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer

, , , , , , & show all
Pages 549-560 | Published online: 20 Jul 2009

REFERENCES

  • Nielsen M. E., Partin A. W. The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev Urol 2007; 9(2)57–62
  • Nguyen P. L., Chen M. H., Catalona W. J., Moul J. W., Sun L., D'Amico A. V. Predicting prostate cancer mortality Among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2008
  • D'Amico A. V., Hui-Chen M., Renshaw A. A., Sussman B., Roehl K. A., Catalona W. J. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 2006; 176(6 Pt 2)S11–15
  • Thompson R. H., Blute M. L., Slezak J. M., Bergstralh E. J., Leibovich B. C. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?. J Urol 2007; 178(2)459–463, discussion 463
  • Eastham J. A., Scardino P. T., Kattan M. W. Predicting an optimal outcome after radical prostatectomy: the Trifecta nomogram. J Urol 2008; 179(6)2207–2210, discussion 2210–2201
  • Roberts W. W., Bergstralh E. J., Blute M. L., Slezak J. M., Carducci M., Han M., Epstein J. I., Eisenberger M. A., Walsh P. C., Partin A. W. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57(6)1033–1037
  • Stephenson A. J., Scardino P. T., Eastham J. A., Bianco F. J., Jr., Dotan Z. A., Fearn P. A., Kattan M. W. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98(10)715–717
  • D'Amico A. V., Chen M. H., Roehl K. A., Catalona W. J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351(2)125–135
  • Hanks G. E., Hanlon A. L., Lee W. R., Slivjak A., Schultheiss T. E. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996; 34(3)549–553
  • Sengupta S., Myers R. P., Slezak J. M., Bergstralh E. J., Zincke H., Blute M. L. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174(6)2191–2196
  • Thompson I. M., Pauler D. K., Goodman P. J., Tangen C. M., Lucia M. S., Parnes H. L., Minasian L. M., Ford L. G., Lippman S. M., Crawford E. D., Crowley J. J., Coltman C. A., Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350(22)2239–2246
  • Blute M. L., Bergstralh E. J., Iocca A., Scherer B., Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165(1)119–125
  • Jones P. A., Baylin S. B. The epigenomics of cancer. Cell 2007; 128(4)683–692
  • Laird P. W. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3(4)253–266
  • Ting A. H., McGarvey K. M., Baylin S. B. The cancer epigenome—components and functional correlates. Genes Dev 2006; 20(23)3215–3231
  • Brueckner B., Kuck D., Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J 2007; 13(1)17–22
  • Egger G., Liang G., Aparicio A., Jones P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429(6990)457–463
  • Moggs J. G., Goodman J. I., Trosko J. E., Roberts R. A. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol 2004; 196(3)422–430
  • Yoo C. B., Jones P. A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5(1)37–50
  • Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Li L. C., Kawahara M., Nakagawa M., Kane C. J., Carroll P. R., Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005; 11(18)6582–6588
  • Vanaja D. K., Ballman K. V., Morlan B. W., Cheville J. C., Neumann R. M., Lieber M. M., Tindall D. J., Young C. Y. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res 2006; 12(4)1128–1136
  • Vanaja D. K., Cheville J. C., Iturria S. J., Young C. Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63(14)3877–3882
  • Ehrich M., Field J. K., Liloglou T., Xinarianos G., Oeth P., Nelson M. R., Cantor C. R., van den Boom D. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 2006; 66(22)10911–10918
  • Freedland S. J., Aronson W. J., Presti J. C., Jr., Amling C. L., Terris M. K., Trock B., Kane C. J. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer 2004; 100(8)1633–1638
  • Stephenson A. J., Kattan M. W., Eastham J. A., Dotan Z. A., Bianco F. J., Jr., Lilja H., Scardino P. T. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24(24)3973–3978
  • Kupelian P. A., Elshaikh M., Reddy C. A., Zippe C., Klein E. A. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002; 20(16)3376–3385
  • Freedland S. J., Sutter M. E., Dorey F., Aronson W. J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61(2)365–369
  • Boorjian S. A., Karnes R. J., Rangel L. J., Bergstralh E. J., Blute M. L. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179(4)1354–1360, discussion 1360–1351
  • Takai D., Jones P. A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002; 99(6)3740–3745
  • Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196(2)261–282
  • Goessl C., Krause H., Muller M., Heicappell R., Schrader M., Sachsinger J., Miller K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000; 60(21)5941–5945
  • Hanson J. A., Gillespie J. W., Grover A., Tangrea M. A., Chuaqui R. F., Emmert-Buck M. R., Tangrea J. A., Libutti S. K., Linehan W. M., Woodson K. G. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006; 98(4)255–261
  • Hampton T. New markers may help predict prostate cancer relapse risk. JAMA 2006; 295(19)2234–2238
  • Li L. C., Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18(11)1427–1431
  • Jornsten R., Yu B. Simultaneous gene clustering and subset selection for sample classification via MDL. Bioinformatics 2003; 19(9)1100–1109
  • Hess K. R., Anderson K., Symmans W. F., Valero V., Ibrahim N., Mejia J. A., Booser D., Theriault R. L., Buzdar A. U., Dempsey P. J., Rouzier R., Sneige N., Ross J. S., Vidaurre T., Gomez H. L., Hortobagyi G. N., Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24(26)4236–4244
  • Tibshirani R., Hastie T., Narasimhan B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99(10)6567–6572
  • Yu Y. P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., McDonald C., Thomas R., Dhir R., Finkelstein S., Michalopoulos G., Becich M., Luo J. H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22(14)2790–2799
  • Singh D., Febbo P. G., Ross K., Jackson D. G., Manola J., Ladd C., Tamayo P., Renshaw A. A., D'Amico A. V., Richie J. P., Lander E. S., Loda M., Kantoff P. W., Golub T. R., Sellers W. R. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1(2)203–209
  • Lapointe J., Li C., Higgins J. P., van de Rijn M., Bair E., Montgomery K., Ferrari M., Egevad L., Rayford W., Bergerheim U., Ekman P., DeMarzo A. M., Tibshirani R., Botstein D., Brown P. O., Brooks J. D., Pollack J. R. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101(3)811–816
  • Dhanasekaran S. M., Barrette T. R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K. J., Rubin M. A., Chinnaiyan A. M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412(6849)822–826
  • Bastian P. J., Palapattu G. S., Lin X., Yegnasubramanian S., Mangold L. A., Trock B., Eisenberger M. A., Partin A. W., Nelson W. G. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005; 11(11)4037–4043
  • Yegnasubramanian S., Kowalski J., Gonzalgo M. L., Zahurak M., Piantadosi S., Walsh P. C., Bova G. S., De Marzo A. M., Isaacs W. B., Nelson W. G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64(6)1975–1986
  • Li L. C., Carroll P. R., Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97(2)103–115
  • Lotan R., Lotan Y. Retinoic acid receptor beta2 hypermethylation: implications for prostate cancer detection, prevention, and therapy. Clin Cancer Res 2004; 10(12 Pt 1)3935–3936
  • Lin X., Tascilar M., Lee W. H., Vles W. J., Lee B. H., Veeraswamy R., Asgari K., Freije D., van Rees B., Gage W. R., Bova G. S., Isaacs W. B., Brooks J. D., DeWeese T. L., De Marzo A. M., Nelson W. G. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001; 159(5)1815–1826
  • Henrique R., Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004; 46(5)660–669, ; discussion 669
  • Bernardini S., Miano R., Iori R., Finazzi-Agro E., Palmieri G., Ballerini S., Angeloni C., Orlandi A., Bellincampi L., Cortese C., Federici G. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?. Clin Chim Acta 2004; 350(1–2)181–188
  • Bastian P. J., Nakayama M., De Marzo A. M., Nelson W. G. [GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer]. Urologe A 2004; 43(5)573–579
  • Rosenbaum E., Hoque M. O., Cohen Y., Zahurak M., Eisenberger M. A., Epstein J. I., Partin A. W., Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005; 11(23)8321–8325
  • Jeronimo C., Henrique R., Hoque M. O., Mambo E., Ribeiro F. R., Varzim G., Oliveira J., Teixeira M. R., Lopes C., Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10(24)8472–8478
  • Kang G. H., Lee S., Lee H. J., Hwang K. S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202(2)233–240
  • Bastian P. J., Ellinger J., Heukamp L. C., Kahl P., Muller S. C., von Rucker A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007; 51(3)665–674
  • Varambally S., Yu J., Laxman B., Rhodes D. R., Mehra R., Tomlins S. A., Shah R. B., Chandran U., Monzon F. A., Becich M. J., Wei J. T., Pienta K. J., Ghosh D., Rubin M. A., Chinnaiyan A. M. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8(5)393–406
  • Nakajima T., Maekita T., Oda I., Gotoda T., Yamamoto S., Umemura S., Ichinose M., Sugimura T., Ushijima T., Saito D. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006; 15(11)2317–2321
  • Maier S., Nimmrich I., Koenig T., Eppenberger-Castori S., Bohlmann I., Paradiso A., Spyratos F., Thomssen C., Mueller V., Nahrig J., Schittulli F., Kates R., Lesche R., Schwope I., Kluth A., Marx A., Martens J. W., Foekens J. A., Schmitt M., Harbeck N. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients—technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer 2007; 43(11)1679–1686
  • Ohba T., Ishino M., Aoto H., Sasaki T. Dot far-western blot analysis of relative binding affinities of the Src homology 3 domains of Efs and its related proteins. Anal Biochem 1998; 262(2)185–192
  • Yue C. M., Deng D. J., Bi M. X., Guo L. P., Lu S. H. Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol 2003; 9(6)1174–1178

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.